Clinical trials: Platelet-aggregation Inhibitors
Peripheral Arterial Disease(PAD)
Effect of Anticoagulant and Antiplatelet Drug Intervention on Postoperative Major Adverse Events in Patients with PAD：Phase II
This study is a multicenter, prospective, observational research project. It is anticipated to enroll a total of 6,000 patients between February 1, 2025, and January 31, 2028 (with completion of one-year postoperative follow-up…
- Trial name
- NCT06850207
- Volunteers
- 6,000 people
- Sponsor
- Chengdu University of Traditional Chinese Medicine
HIV Infections, Hemophilia A
Effect of Indinavir Plus Two Other Anti-HIV Drugs on Blood Clotting in HIV-Positive Males With Hemophilia
The purpose of this study is to see if indinavir plus two other anti-HIV drugs affect blood clotting in HIV-positive patients with hemophilia.
- Trial name
- NCT00002386
- Testing
- Indinavir sulfate, Lamivudine, Stavudine
- Where
- 8 sites in United States, Canada
- Volunteers
- 55 people
- Sponsor
- Merck Sharp & Dohme LLC
Acute Coronary Syndrome, Acute Myocardial Infarction
ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study for the Patients With ACS
The purpose of this study is to evaluate the safety of reducing dual antiplatelet therapy (DAPT) duration to 1 month after implantation of the everolimus-eluting cobalt-chromium stent (CoCr-EES) under the setting of acute…
- Conditions
- Acute Coronary Syndrome, Acute Myocardial Infarction, Coronary Artery Disease, Percutaneous Coronary Intervention
- Trial name
- STOPDAPT-2 ACS (NCT03462498)
- Testing
- 1-months DAPT, 12-month DAPT
- Where
- Japan
- Volunteers
- 3,008 people
- Sponsor
- Kyoto University, Graduate School of Medicine
Mitral Regurgitation
STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients Without an Indication for Oral Anticoagulant
Mitral regurgitation (MR) is the most common valvular heart disease, affecting approximately 24.2 million people worldwide (with a higher prevalence in older age groups).
- Trial name
- STAR-TEER Ⅱ (NCT07007143)
- Testing
- Experimental: Aspirin monotherapy, Active Comparator: Aspirin+Clopidogrel
- Where
- China
- Volunteers
- 1,032 people
- Sponsor
- Chinese Academy of Medical Sciences, Fuwai Hospital
Coronary Disease, Heart Diseases
Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO IV-EPIC 38)
This international, multicenter, open-label, randomized clinical trial evaluates the safety and efficacy of single antiplatelet therapy (SAPT) compared to dual antiplatelet therapy (DAPT) in elderly or high bleeding risk patients…
- Conditions
- Coronary Disease, Heart Diseases, Cardiovascular Diseases, Myocardial Ischemia
- Trial name
- PIV-EPIC (NCT06535568)
- Testing
- Drug-coated balloon, Single antiplatelet therapy (SAPT), Dual antiplatelet therapy (DAPT)
- Where
- Italy
- Volunteers
- 576 people
- Sponsor
- Fondazione Ricerca e Innovazione Cardiovascolare ETS
Platelet Aggregation Inhibitors, Hydroxymethylglutaryl-coa Reductase Inhibitors
The Compliance of DAPT and Statins on Clinical Outcomes in Percutaneous Coronary Intervention Patients
A nationwide retrospective cohort study. To investigate the real world medication compliance and the relation with clinical outcomes.
- Conditions
- Platelet Aggregation Inhibitors, Hydroxymethylglutaryl-coa Reductase Inhibitors, Compliance, Medication, Adherence, Medication
- Trial name
- CPPCI (NCT03785509)
- Testing
- DAPT, Statin
- Where
- South Korea
- Volunteers
- 47,291 people
- Sponsor
- Samsung Medical Center
Myocardial Infarction (MI)
Patient Characteristics, Persistence to Treatment and Outcome Events in Patients Treated With Ticagrelor 60 mg After Myocardial Infarction in Real-world Clinical Practice
This is an observational study based on secondary data extracted from multiple register-based data sources in the US and Europe (Sweden, United Kingdom, Italy, Germany).
- Trial name
- ALETHEIA (NCT04568083)
- Where
- 6 sites in United States, Germany and 3 more
- Volunteers
- 7,035 people
- Sponsor
- AstraZeneca
Coronary Artery Disease
ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study
The purpose of this study is to evaluate the safety of reducing dual antiplatelet therapy (DAPT) duration to 1 month after implantation of the everolimus-eluting cobalt-chromium stent (CoCr-EES).
- Trial name
- STOPDAPT-2 (NCT02619760)
- Testing
- 1-month DAPT, 12-month DAPT
- Where
- Japan
- Volunteers
- 3,045 people
- Sponsor
- Kyoto University, Graduate School of Medicine
Renal Failure, Coronary Artery Disease
Effect of Haemodialysis on the Efficacy of Antiplatelet Agents
The main purpose of our study is to investigate whether haemodialysis itself affects the efficacy of antiplatelet drugs and the effects of two different types of dialysis membranes (polysulfone membranes and polyamide membranes)…
- Conditions
- Renal Failure, Coronary Artery Disease, Hemolysis
- Trial name
- NCT03330223
- Testing
- Clopidogrel group;Ticagrelor group
- Where
- China
- Volunteers
- 60 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Coronary Artery Disease
SAfety and EFficacy of Bridging Antithrombotic Therapy During Elective Non-cardiac Surgery
Patients with coronary artery disease, especially after PCI, require long-term oral antiplatelet therapy. However, this patient population may inevitably require non-cardiac surgery for a variety of conditions.
- Trial name
- SAFE (NCT04675801)
- Where
- China
- Volunteers
- 950 people
- Sponsor
- Beijing Anzhen Hospital
Acute Coronary Syndrome, Atrial Fibrillation
Ongoing WARfarin and Coronary STENTing
Patients on warfarin treatment pose particular problems when undergoing percutaneous coronary intervention with stent implantation (PCI-S), because of the poor definition of the optimal antithrombotic strategies to be adopted…
- Trial name
- WAR-STENT (NCT00722319)
- Where
- Italy
- Volunteers
- 1,000 people
- Sponsor
- War-Stent Investigators
Coronary Artery Disease, Coronary Artery Stenosis
Nationwide Cohort Study of Antiplatelet Agents as Primary Prevention
There is no specific recommendation regarding pharmacologic treatment as primary prevention for patients with intermediate coronary artery stenosis whose revascularization was deferred based on negative fractional flow reserve…
- Trial name
- NHIS (NCT06281041)
- Testing
- Antiplatelet Agents
- Where
- South Korea
- Volunteers
- 4,657 people
- Sponsor
- Samsung Medical Center
Mitral Regurgitation
STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients With an Indication for Oral Anticoagulant
Mitral regurgitation (MR) is the most common valvular heart disease, affecting approximately 24.2 million people worldwide (with a higher prevalence in older age groups).
- Trial name
- STAR-TEER Ⅰ (NCT06901466)
- Testing
- Experimental: Rivaroxaban monotherapy, Active Comparator: Rivaroxaban+Clopidogrel
- Where
- China
- Volunteers
- 880 people
- Sponsor
- Chinese Academy of Medical Sciences, Fuwai Hospital
Drug Effect Disorder, Platelet Procoagulant Activity Deficiency
the Effect Between Platelet Reactivation and Antiplatelet Drugs
Different antiplatelet drugs played various role in coronary artery disease. The mechanisms were unclear. Platelet reactivation maybe was one of major causes.
- Trial name
- NCT02198053
- Where
- China
- Volunteers
- 74 people
- Sponsor
- Beijing Anzhen Hospital
Hip Fracture
Hip-Fracture Surgery on Patients in Clopidogrel Therapy
Patients in Clopidogrel therapy alone or in combination with acetylsalicylic acid (Dual Antiplatelet Therapy (DAPT) presenting with a hip-fracture represent the surgeon with the dilemma of putting the patient at risk of a major…
- Trial name
- NCT02391883
- Testing
- Clopidogrel
- Volunteers
- 356 people
- Sponsor
- Hvidovre University Hospital
Acute Coronary Syndrome
ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-3 Study
The purpose of this study is to explore the benefit of the prasugrel monotherapy without aspirin as compared with the 1-month dual therapy with aspirin and prasugrel in terms of reducing bleeding events after percutaneous…
- Trial name
- STOPDAPT-3 (NCT04609111)
- Testing
- No aspirin, 1-month DAPT
- Where
- Japan
- Volunteers
- 6,002 people
- Sponsor
- Kyoto University, Graduate School of Medicine